查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1356769

女性不孕診斷與治療市場報告：2030 年趨勢、預測與競爭分析

Female Infertility Diagnosis and Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

女性不孕診斷和治療的趨勢和預測

預計到2030年，全球女性不孕診斷和治療市場將達20億美元，2024年至2030年年複合成長率為7.7%。這個市場的主要促進因素是唐氏症、ONTD 和其他疾病等遺傳疾病的患病、對可避免治療的認知不斷增強以及輔助生殖技術的進步。全球女性不孕診療市場前景廣闊，醫院/診所、居家醫療、病理/診斷中心市場蘊藏商機。

女性不孕診療市場洞察

Lucintel 預測，由於治療女性不孕的技術不斷進步，包括體外受精 (IVF)、人工授精 (AI-IUI) 和冷凍胚胎移植 (FET) 等，輔助生殖技術將在預測期內繼續成長。預計增幅最高的是

在這個市場中，由於擁有龐大的基本客群以及醫生擴大採用新技術先進的做法，醫院和診所可能仍然是最大的細分市場。

由於不孕相關問題的普遍存在和醫療保健支出的增加，預計亞太地區在預測期內將出現最高的成長。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要要素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些，由於材料或產品替代導致市場佔有率下降的威脅有多大？
  • Q.1.1.過去年度發生了哪些類型的併購，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球女性不孕診斷與治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球女性不孕診斷及治療市場趨勢（2018-2023）及預測（2024-2030）
  • 全球女性不孕診斷與治療市場（依治療方式）
    • 藥品
    • 外科手術
    • 子宮腔內人工授精
    • 輔助生殖技術
  • 全球女性不孕診斷和治療市場（按診斷）
    • 排卵測試
    • 造影
    • 子宮鏡檢查
    • 影像檢查
    • 卵巢儲備測試
    • 荷爾蒙水平測試
    • 基因檢測
    • 其他
  • 全球女性不孕診斷和治療市場（按最終用途）
    • 醫院/診所
    • 居家醫療
    • 病理/診斷中心
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球女性不孕診斷與治療市場（按地區）
  • 北美女性不孕診療市場
  • 歐洲女性不孕診療市場
  • 亞太女性不孕診療市場
  • 其他地區女性不孕診療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球女性不孕診斷和治療市場成長機會（按治療）
    • 全球女性不孕診斷和治療市場成長機會（按診斷）
    • 按最終用途的全球女性不孕診斷和治療市場的成長機會
    • 全球女性不孕診斷與治療市場按地區成長機會
  • 全球女性不孕診療市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球女性不孕診斷和治療市場的容量
    • 全球女性不孕診斷和治療市場的合併和收購
    • 認證和許可

第7章 主要企業概況

  • Bayer AG
  • Church & Dwight
  • Genea
  • Pfizer
  • Vitrolife Sweden AB
  • Esco Group
  • Fairhaven Health
  • Ferring BV
簡介目錄

Female Infertility Diagnosis and Treatment Trends and Forecast

The future of the global female infertility diagnosis and treatment market looks promising with opportunities in the hospitals & clinic, homecare, and pathology & diagnostic centers markets. The global female infertility diagnosis and treatment market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 7.7% from 2024 to 2030. The major drivers for this market are growing prevalence of genetic disorders, such as Down syndrome, ONTD, and other disorders, increasing awareness towards avialable treatment, and technological advancement of assisted reproductive technology.

A more than 150-page report is developed to help in your business decisions.

Female Infertility Diagnosis and Treatment by Segment

The study includes a forecast for the global female infertility diagnosis and treatment by treatment, diagnosis, end use, and region.

Female Infertility Diagnosis and Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Drugs
  • Surgery
  • Intrauterine Insemination
  • Assisted Reproductive Technology

Female Infertility Diagnosis and Treatment Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Ovulation Testing
  • Hysterosalpingography
  • Hysteroscopy
  • Imaging Testing
  • Ovarian Reserve Testing
  • Hormonal Level Testing
  • Genetic Testing
  • Others

Female Infertility Diagnosis and Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Homecare
  • Pathology and Diagnostic Centers
  • Others

Female Infertility Diagnosis and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Female Infertility Diagnosis and Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies female infertility diagnosis and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the female infertility diagnosis and treatment companies profiled in this report include-

  • Bayer Ag
  • Church & Dwight
  • Genea
  • Pfizer
  • Vitrolife Sweden Ab
  • Esco Group
  • Fairhaven Health
  • Ferring B.V.

Female Infertility Diagnosis and Treatment Market Insights

Lucintel forecasts that assisted reproductive technology is expected to witness highest growth over the forecast period due to on-going technological advancements, which includes in vitro fertilization (IVF), artificial insemination(AI-IUI), and frozen embryo transfer(FET for treating infertility in women.

Within this market, hospitals and clinics will remain the largest segment due to presence of large customer base and growing adoption of new technologically advanced practices by doctors.

Asia Pacific is expected to witness highest growth over the forecast period due to prevalence of infertility-related issues and increasing expenditure on healthcare in the region.

Features of the Global Female Infertility Diagnosis and Treatment Market

Market Size Estimates: Female infertility diagnosis and treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Female infertility diagnosis and treatment market size by treatment, diagnosis, end use, and region. in terms of value ($B).

Regional Analysis: Female infertility diagnosis and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, diagnosis, end uses, and region.s for the female infertility diagnosis and treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the female infertility diagnosis and treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the female infertility diagnosis and treatment market size?

Answer: The global female infertility diagnosis and treatment market is expected to reach an estimated $2.0 billion by 2030.

Q.2. What is the growth forecast for female infertility diagnosis and treatment market?

Answer: The global female infertility diagnosis and treatment market is expected to grow with a CAGR of 7.7% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the female infertility diagnosis and treatment market?

Answer: The major drivers for this market are growing prevalence of genetic disorders, such as Down syndrome, ONTD, and other disorders, increasing awareness towards avialable treatment, and technological advancement of assisted reproductive technology.

Q.4. What are the major segments for female infertility diagnosis and treatment market?

Answer: The future of the female infertility diagnosis and treatment market looks promising with opportunities in the hospitals & clinic, homecare, and pathology & diagnostic centers markets.

Q.5. Who are the key female infertility diagnosis and treatment market companies?

Answer: Some of the key female infertility diagnosis and treatment companies are as follows:

  • Bayer AG
  • Church & Dwight
  • Genea
  • Pfizer
  • Vitrolife Sweden AB
  • Esco Group
  • Fairhaven Health
  • Ferring B.V.

Q.6. Which female infertility diagnosis and treatment market segment will be the largest in future?

Answer: Lucintel forecasts that assisted reproductive technology is expected to witness highest growth over the forecast period due to on-going technological advancements, which includes in vitro fertilization (IVF), artificial insemination(AI-IUI), and frozen embryo transfer(FET for treating infertility in women.

Q.7. In female infertility diagnosis and treatment market, which region is expected to be the largest in next 5 years?

Answer: Asia Pacific is expected to witness highest growth over the forecast period due to prevalence of infertility-related issues and increasing expenditure on healthcare in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the female infertility diagnosis and treatment market by treatment (drugs, surgery, intrauterine insemination, and assisted reproductive technology), diagnosis (ovulation testing, hysterosalpingography, hysteroscopy, imaging testing, ovarian reserve testing, hormonal level testing, genetic testing, and others), end use (hospitals & clinics, homecare, pathology & diagnostic centers, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.1. 1. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Female Infertility Diagnosis and Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Female Infertility Diagnosis and Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Female Infertility Diagnosis and Treatment Market by Treatment
    • 3.3.1: Drugs
    • 3.3.2: Surgery
    • 3.3.3: Intrauterine Insemination
    • 3.3.4: Assisted Reproductive Technology
  • 3.4: Global Female Infertility Diagnosis and Treatment Market by Diagnosis
    • 3.4.1: Ovulation Testing
    • 3.4.2: Hysterosalpingography
    • 3.4.3: Hysteroscopy
    • 3.4.4: Imaging Testing
    • 3.4.5: Ovarian Reserve Testing
    • 3.4.6: Hormonal Level Testing
    • 3.4.7: Genetic Testing
    • 3.4.8: Others
  • 3.5: Global Female Infertility Diagnosis and Treatment Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Homecare
    • 3.5.3: Pathology and Diagnostic Centers
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Female Infertility Diagnosis and Treatment Market by Region
  • 4.2: North American Female Infertility Diagnosis and Treatment Market
    • 4.2.2: North American Female Infertility Diagnosis and Treatment Market by End Use: Hospitals and Clinics, Homecare, Pathology and Diagnostic Centers, and Others
  • 4.3: European Female Infertility Diagnosis and Treatment Market
    • 4.3.1: European Female Infertility Diagnosis and Treatment Market by Treatment: Drugs, Surgery, Intrauterine Insemination, and Assisted Reproductive Technology
    • 4.3.2: European Female Infertility Diagnosis and Treatment Market by End Use: Hospitals and Clinics, Homecare, Pathology and Diagnostic Centers, and Others
  • 4.4: APAC Female Infertility Diagnosis and Treatment Market
    • 4.4.1: APAC Female Infertility Diagnosis and Treatment Market by Treatment: Drugs, Surgery, Intrauterine Insemination, and Assisted Reproductive Technology
    • 4.4.2: APAC Female Infertility Diagnosis and Treatment Market by End Use: Hospitals and Clinics, Homecare, Pathology and Diagnostic Centers, and Others
  • 4.5: ROW Female Infertility Diagnosis and Treatment Market
    • 4.5.1: ROW Female Infertility Diagnosis and Treatment Market by Treatment: Drugs, Surgery, Intrauterine Insemination, and Assisted Reproductive Technology
    • 4.5.2: ROW Female Infertility Diagnosis and Treatment Market by End Use: Hospitals and Clinics, Homecare, Pathology and Diagnostic Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Female Infertility Diagnosis and Treatment Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Female Infertility Diagnosis and Treatment Market by Diagnosis
    • 6.1.3: Growth Opportunities for the Global Female Infertility Diagnosis and Treatment Market by End Use
    • 6.1.4: Growth Opportunities for the Global Female Infertility Diagnosis and Treatment Market by Region
  • 6.2: Emerging Trends in the Global Female Infertility Diagnosis and Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Female Infertility Diagnosis and Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Female Infertility Diagnosis and Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bayer AG
  • 7.2: Church & Dwight
  • 7.3: Genea
  • 7.4: Pfizer
  • 7.5: Vitrolife Sweden AB
  • 7.6: Esco Group
  • 7.7: Fairhaven Health
  • 7.8: Ferring B.V.